The collapse of Theranos and the subsequent travails of its founder, Elizabeth Holmes, may well have cooled somewhat the formerly white-hot search of venture capitalists for the next great high-tech unicorn.
After the verdict, Bijan Salehizadeh, holder of an MD from the Columbia University College of Physicians and Surgeons (1999), and an investor at Highland Capital Partners, reminisced for The New York Times about his reluctance to invest in Theranos in its early years, and how he came to question that judgment while listening to the venture capitalists hanging out at the Rosewood . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
